Biodesix Inc. (BDSX) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, BDSX scores 42 out of 100, graded D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 9/20 (ROIC of -35% and FCF yield of -9.02%), Whale 13F Flow at 10/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta of 1.0 and sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z of 2.5, Piotroski F of 4/9, Debt/Equity of 0.5). The weakest pillar is Insider Conviction, which sits at the bottom of the scale. The strongest is Forensic Balance Sheet, which is still below half of its available points. For a prospective investor, the implication is that the cash-generation engine is the central weakness: negative ROIC and negative FCF yield indicate that the business is not currently converting capital into owner returns. The forensic metrics suggest the balance sheet is not in acute distress but is not a source of strength either. The price has moved sharply within a wide 52-week range ($5.26 - $31.97), so valuation tradeoffs depend heavily on whether recent flow reflects a durable re-rating or a volatile swing. An upside case would require evidence that operating losses are narrowing; the source data does not show that trajectory clearly.

Biodesix Inc. (BDSX) is a NASDAQ-listed issuer classified in the Health Care sector and the Medical Specialities industry. Per the profile, the company has a market capitalization of $0.3B. The source data does not detail its product lines, customer base, or revenue model. Revenue figures appear in the SEC financials below, but the source data does not describe how that revenue is generated.

Per the SEC financials, revenue rose from $49.1M in FY 2023 to $88.5M in FY 2025, while operating losses narrowed from $-41.3M to $-27.9M over the same span. Net losses also narrowed, from $-52.1M to $-35.3M. Per the market data, operating margin is -31.5%, net margin is -39.9%, and gross margin is 0%. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5, which together describe a balance sheet that is neither clearly distressed nor clearly healthy. Reported cash declined from $26.2M to $19.0M in FY 2025.

Per the recent news and catalysts section, the most prominent item is a Yahoo Finance report headlined "Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth," tagged as a catalyst (green signal). A Stock Titan item titled "A new six-step lung nodule plan puts risk-assessment tests at its core" is tagged as a risk watch (red signal). Four other items are tagged as market wire (yellow signals), including MarketBeat and Yahoo Finance pieces on earnings expectations and share-price movement. One headline references an expectation of negative earnings for an upcoming period. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

• What are the company's specific products and revenue sources, given that the source data gives revenue figures without describing them?
• Why are EPS, debt, and cash for FY 2023 missing, and what is the company's full debt position?
• What is the reported basis for the "fair value lift" and "MRD growth" referenced in the catalyst headline, and does it reflect company-level results?
• What drove the stock from a 52-week low of $5.26 to a high of $31.97, and how much of that move reflects institutional versus retail flow?
• Does the narrowing of operating losses across FY 2023 to FY 2025 represent a sustained trend that would move the Fundamental Cash Engine pillar?